(Total Views: 309)
Posted On: 02/09/2021 11:15:28 AM
Post# of 36568
Seems like the negs are coming out of the woodwork...agreed that the CC could have gone much differently, and hopefully they will fix it in the future, but technical glitches happen and with over 8000 callers it was likely the infrastructure didn’t hold.
In my opinion no CEO of any publicly held company should not have any social media presence aside from a LinkedIn page.
It does seem like some posters have a personal issue with Joe and is unfortunately are kitchen-sinking him for woes that aren’t necessarily Joe’s responsibility. For those calling for his replacement, do you really believe that this would be good timing to do that? I think that Joe is actually doing fine aside from his former rants on this board and others which it seems like he curtailed in 2020.
He and his team have been working hard to get this done and we are very nearly there to a strong IPO with NGIO.
It’s true that the Generex PR machine could be doing better, and on similar news we are seeing nasdaq listed companies jump to $18/share. It seems the takeaway is that we have much to look forward to as NGIO is situated to have both the good transgenic mouse data plus it’s already in the fda process so we will be well ahead of the other small players biding for the small-company entry. Our data is strong and we will be noticed in time.
Moreover GNBT is already ahead of those companies in terms of commercialization. OUS is a tremendous opportunity, and with Moderna and Pfizer vaccines not providing strong memory, we are very well positioned for success domestically as well. It’s a challenging time to be patient, but we must exercise it at this time.
In my opinion no CEO of any publicly held company should not have any social media presence aside from a LinkedIn page.
It does seem like some posters have a personal issue with Joe and is unfortunately are kitchen-sinking him for woes that aren’t necessarily Joe’s responsibility. For those calling for his replacement, do you really believe that this would be good timing to do that? I think that Joe is actually doing fine aside from his former rants on this board and others which it seems like he curtailed in 2020.
He and his team have been working hard to get this done and we are very nearly there to a strong IPO with NGIO.
It’s true that the Generex PR machine could be doing better, and on similar news we are seeing nasdaq listed companies jump to $18/share. It seems the takeaway is that we have much to look forward to as NGIO is situated to have both the good transgenic mouse data plus it’s already in the fda process so we will be well ahead of the other small players biding for the small-company entry. Our data is strong and we will be noticed in time.
Moreover GNBT is already ahead of those companies in terms of commercialization. OUS is a tremendous opportunity, and with Moderna and Pfizer vaccines not providing strong memory, we are very well positioned for success domestically as well. It’s a challenging time to be patient, but we must exercise it at this time.
(5)
(0)
